Giacopelli Pietro, Cristaudi Alessandra, Majno Pietro, Roesel Raffaello, Iaquinandi Fabiano, Mongelli Francesco
Department of Surgery, Ospedale Regionale di Bellinzona e Valli, EOC, Bellinzona, Switzerland.
Department of Surgery, Ospedale Regionale di Lugano, EOC, Lugano, Switzerland.
Front Surg. 2024 Apr 8;11:1393948. doi: 10.3389/fsurg.2024.1393948. eCollection 2024.
During the Sars-Cov-2 crisis, some of the resources committed to emergency surgery services were transiently reallocated to the care of patients with severe COVID-19, preserving immediate treatment of mostly non-deferrable conditions. Moreover, the fear of contracting infections or hindering the treatment of critical COVID-19 patients has caused many individuals to defer seeking emergency care. This situation has then possibly modified the standard of care of some common surgical conditions and the relative outcomes. Our aims was to highlight any difference in surgical outcomes in patients treated for acute cholecystitis before and during the COVID-19 outbreak.
This is a retrospective study on a prospectively collected database that included all consecutive patients treated for acute cholecystitis from March 2019 to February 2021 at the Lugano Regional Hospital, a COVID-free hospital for general surgery patients. Patients were divided into pre-and post-COVID-19 outbreak groups. We collected thorough clinical characteristics and intra-and postoperative outcomes.
We included 124 patients, of which 60 and 64 were operated on before and after the COVID-19 outbreak respectively. The two groups resulted similar in terms of patients' clinical characteristics (age, gender, body mass index, ASA score, and comorbidities). Patients in the post-outbreak period were admitted to the hospital 0.7 days later than patients in the pre-outbreak period (3.8 ± 6.0 days vs. 3.1 ± 4.1 days, = 0.453). Operative time, recovery room time, complications, and reoperations resulted similar between groups. More patients in the post-outbreak period received postoperative antibiotic therapy (63.3% vs. 37.5%, = 0.004) and for a longer time (6.9 ± 5.1 days vs. 4.5 ± 3.9 days, = 0.020). No significant histopathological difference was found in operatory specimens.
Despite more frequent antibiotic therapy that suggests eventually worse inflammatory local status, our results showed similar outcomes for patients treated for acute cholecystitis before and during the COVID-19 pandemic. The local COVID management, reallocating resources, and keeping COVID-free hospitals was key to offering patients a high standard of treatment.
在严重急性呼吸综合征冠状病毒2(Sars-Cov-2)危机期间,一些用于急诊手术服务的资源被临时重新分配用于治疗重症2019冠状病毒病(COVID-19)患者,以确保对大多数不能推迟治疗的疾病进行即时治疗。此外,担心感染或妨碍重症COVID-19患者的治疗导致许多人推迟寻求急诊治疗。这种情况可能改变了一些常见外科疾病的治疗标准及相关治疗结果。我们的目的是突出在COVID-19疫情之前和期间接受急性胆囊炎治疗的患者手术结果的差异。
这是一项对前瞻性收集的数据库进行的回顾性研究,该数据库包括2019年3月至2021年2月在卢加诺地区医院接受急性胆囊炎治疗的所有连续患者,该医院是一家普通外科患者的无COVID医院。患者被分为COVID-19疫情前和疫情后两组。我们收集了详尽的临床特征以及术中和术后结果。
我们纳入了124例患者,其中60例和64例分别在COVID-19疫情之前和之后接受手术。两组患者的临床特征(年龄、性别、体重指数、美国麻醉医师协会(ASA)评分和合并症)相似。疫情后时期的患者比疫情前时期的患者晚0.7天入院(3.8±6.0天对3.1±4.1天,P = 0.453)。两组之间的手术时间、恢复室时间、并发症和再次手术情况相似。疫情后时期更多患者接受了术后抗生素治疗(63.3%对37.5%,P = 0.004),且治疗时间更长(6.9±5.1天对4.5±3.9天,P = 0.020)。手术标本未发现明显的组织病理学差异。
尽管抗生素治疗更频繁表明最终局部炎症状态更差,但我们的结果显示,在COVID-19大流行之前和期间接受急性胆囊炎治疗的患者结果相似。当地的COVID管理、资源重新分配以及保持无COVID医院是为患者提供高标准治疗的关键。